Search
Selected Filters
Filter Results
Displaying 1–10 of 267 research results
-
May 2, 2024
Atsena’s XLRS Gene Therapy Shows Efficacy in Phase 1/2 Clinical Trial
The XLRS gene therapy was well tolerated and resolved damaging schisis cavities in patients receiving the lowest dose.
-
Apr 19, 2024
SalioGen Developing Novel Gene Insertion Therapy for Stargardt Disease
The company’s innovative Gene Coding™ platform enables seamless insertion of DNA into selective genomic locations.
-
Apr 12, 2024
Phase 3 Clinical Trial of NAC Launched for RP Patients
The drug is thought to work independent of the mutated gene causing RP.
-
Apr 11, 2024
ViGeneron Launches Clinical Trial of Gene Therapy for RP Caused by CNGA1 Mutations
The gene therapy is administered using a less-invasive intravitreal injection.
-
Apr 8, 2024
Ocugen to Launch Phase 3 Clinical Trial of Modifier Gene Therapy for RP
The emerging treatment is designed to work independent of the patient’s mutated gene.
-
Mar 27, 2024
Nanoscope Plans to Apply for FDA Approval for its Optogenetic Therapy
The company reported positive two-year results for its Phase 2 clinical trial of MCO-010.
-
Mar 26, 2024
Opus Reports Vision Improvements for Patients in LCA5 Gene Therapy Clinical Trial
The company plans to administer a higher dose of the emerging gene therapy to the next group of patients.
-
Feb 21, 2024
jCyte Announces Plans to Launch Phase 3 Clinical Trial of Cell Therapy for RP
Known as retinal progenitors, the company’s jCells® are designed to preserve photoreceptors in people with retinitis pigmentosa (RP) and other retinal diseases.
-
Feb 9, 2024
The company plans to begin a Phase 2/3 clinical trial for the treatment during the first half of 2024.
-
Feb 1, 2024
Ascidian to Launch Clinical Trial for Stargardt Disease RNA Editing Therapy
ACDN-01 is the only genetic medicine entering clinical development for Stargardt disease.